Join to View Full Profile
11755 SW 90th StreetSuite 205Miami, FL 33186
Phone+1 305-274-6002
Fax+1 305-274-7970
Dr. Gersten is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Miami/Jackson Health SystemResidency, Obstetrics and Gynecology, 1979 - 1983
Icahn School of Medicine at Mount SinaiClass of 1979
Certifications & Licensure
FL State Medical License 1982 - 2026
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
Awards, Honors, & Recognition
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Start of enrollment: 2017 Aug 01
- LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women Start of enrollment: 2022 Mar 28
Publications & Presentations
PubMed
- 46 citationsIbrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)Jane R. Schwebke, Ryan Sobel, Janet K Gersten, Steven A Sussman, Samuel N. Lederman
Clinical Infectious Diseases. 2021-09-01 - 17 citationsA rapid, high-volume cervical screening project using self-sampling and isothermal PCR HPV testingAndrew T. Goldstein, Yang Lei, Lena Goldstein, Amelia R Goldstein, Qiao Xu Bai
Infectious Agents and Cancer. 2020-10-22 - 10 citationsA Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescen...Steven E. Chavoustie, Janet K Gersten, Milroy J Samuel, Jane R. Schwebke
Journal of Women's Health. 2018-01-11
Authored Content
- A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 G for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial VaginosisJanuary 2018
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
